The Goldman Sachs Group, Inc. (GS) Stock Forecast
Data as of May 2, 2026Financial Services · Current price $926.49 (+0.30%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Apr 14, 2026 | Ebrahim Poonawala | Goldman Sachs | $1050.00 | +13.3% |
| Jan 20, 2026 | Gerard Cassidy | RBC Capital | $1030.00 | +11.2% |
| Jan 16, 2026 | Christopher McGratty | Keefe Bruyette | $1000.00 | +7.9% |
| Jan 16, 2026 | Glenn Schorr | Evercore ISI | $1075.00 | +16.0% |
| Oct 21, 2025 | Kian Abouhossein | J.P. Morgan | $750.00 | -19.0% |
| Oct 15, 2025 | Jason Goldberg | Barclays | $850.00 | -8.3% |
| Jul 10, 2025 | Glenn Schorr | Evercore ISI | $715.00 | -22.8% |
| Jul 10, 2025 | Mike Mayo | Wells Fargo | $785.00 | -15.3% |
| Apr 15, 2025 | Gerard Cassidy | RBC Capital | $560.00 | -39.6% |
| Apr 15, 2025 | Mike Mayo | Wells Fargo | $650.00 | -29.8% |
| Apr 7, 2025 | Betsy Graseck | Morgan Stanley | $558.00 | -39.8% |
| Oct 16, 2024 | Chris Kotowski | Oppenheimer | $614.00 | -33.7% |
| Oct 16, 2024 | Daniel Fannon | Jefferies | $609.00 | -34.3% |
| Oct 16, 2024 | Glenn Schorr | Evercore ISI | $575.00 | -37.9% |
| Oct 16, 2024 | Jason Goldberg | Barclays | $588.00 | -36.5% |
| Oct 15, 2024 | Kenneth Leon | CFRA | $585.00 | -36.9% |
| Oct 9, 2024 | Devin Ryan | JMP Securities | $550.00 | -40.6% |
| Sep 30, 2024 | Betsy Graseck | Morgan Stanley | $560.00 | -39.6% |
| Sep 10, 2024 | Kenneth Leon | CFRA | $553.00 | -40.3% |
| Sep 9, 2024 | Kian Abouhossein | J.P. Morgan | $472.00 | -49.1% |
Top Analysts Covering GS
GS vs Sector & Market
| Metric | GS | Financial Services Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.54 | 2.51 | 2.41 |
| Analyst Count | 13 | 8 | 18 |
| Target Upside | +7.5% | +64.9% | +14.9% |
| P/E Ratio | 16.92 | -5.02 | 31.19 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $61.50B | $63.51B | $65.50B | 14 |
| 2027-12-31 | $62.42B | $66.58B | $70.60B | 15 |
| 2028-03-31 | $17.16B | $17.73B | $18.42B | 3 |
| 2028-06-30 | $16.41B | $16.95B | $17.61B | 3 |
| 2028-09-30 | $16.29B | $16.83B | $17.49B | 5 |
| 2028-12-31 | $16.18B | $16.72B | $17.37B | 3 |
| 2029-03-31 | $16.77B | $17.33B | $18.01B | 4 |
| 2029-06-30 | $17.26B | $17.84B | $18.53B | 4 |
| 2029-09-30 | $17.07B | $17.64B | $18.33B | 7 |
| 2029-12-31 | $16.47B | $17.02B | $17.68B | 4 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $54.32 | $59.09 | $64.35 | 18 |
| 2027-12-31 | $58.30 | $65.06 | $73.44 | 17 |
| 2028-03-31 | $19.30 | $20.15 | $21.17 | 5 |
| 2028-06-30 | $17.08 | $17.83 | $18.74 | 7 |
| 2028-09-30 | $17.20 | $17.95 | $18.86 | 10 |
| 2028-12-31 | $17.67 | $18.45 | $19.38 | 5 |
| 2029-03-31 | $0.00 | $0.00 | $0.00 | 5 |
| 2029-06-30 | $0.00 | $0.00 | $0.00 | 7 |
| 2029-09-30 | $0.00 | $0.00 | $0.00 | 4 |
| 2029-12-31 | $0.00 | $0.00 | $0.00 | 4 |
Frequently Asked Questions
What is the analyst consensus for GS?
The consensus among 13 analysts covering The Goldman Sachs Group, Inc. (GS) is Hold with an average price target of $915.15.
What is the highest price target for GS?
The highest price target for GS is $1075.00, set by Glenn Schorr at Evercore ISI on 2026-01-16.
What is the lowest price target for GS?
The lowest price target for GS is $290.00, set by John Heagerty at Goldman Sachs on 2022-10-05.
How many analysts cover GS?
13 analysts have issued ratings for The Goldman Sachs Group, Inc. in the past 12 months.
Is GS a buy or sell right now?
Based on 13 analyst ratings, GS has a consensus rating of Hold (2.54/5) with a +7.5% upside to the consensus target of $915.15.
What are the earnings estimates for GS?
Analysts estimate GS will report EPS of $59.09 for the period ending 2026-12-31, with revenue estimated at $63.51B.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.